NCT03454035View on ClinicalTrials.gov

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

July 15, 2026

Study Completion Date

November 24, 2026

Conditions
Tumor, SolidPancreatic CancerMelanoma
Interventions
DRUG

Ulixertinib

Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib

DRUG

Palbociclib

Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors
All Listed Sponsors
collaborator

BioMed Valley Discoveries, Inc

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT03454035 - Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | Biotech Hunter | Biotech Hunter